Accuray Inc(ARAY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 5:57 PM ET (Korea 11/3 07:57)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.41 | Insider Own | 4.46% | Shs Outstand | 119.4M | Perf Week | 20.23% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 114.2M | Perf Month | -47.33% |
| Enterprise Value | 0.16B | PEG | - | EPS next Q | - | Inst Own | 44.34% | Short Float | 4.42% | Perf Quarter | -52.44% |
| Income | -0.05B | P/S | 0.04 | EPS this Y | - | Inst Trans | -8.1% | Short Ratio | 0.7 | Perf Half Y | -67.83% |
| Sales | 0.40B | P/B | 0.42 | EPS next 5Y | - | ROA | -10.77% | Short Interest | 5.05M | Perf YTD | -82.05% |
| Book/sh | 0.35 | P/C | 0.43 | EPS past 3/5Y | -60.07% -42.36% | ROE | -80.08% | 52W High | -89.86% ($1.46) | Perf Year | -89.5% |
| Cash/sh | 0.34 | P/FCF | - | Sales past 3/5Y | -3.52% 0.28% | ROIC | -22.79% | 52W Low | 20.82% ($0.12) | Perf 3Y | -94.35% |
| Dividend Est. | - | EV/EBITDA | 80.88 | EPS Y/Y TTM | -2363.03% | Gross Margin | 27.71% | Volatility(W/M) | 8.37% 12% | Perf 5Y | -97.24% |
| Dividend TTM | - | EV/Sales | 0.41 | Sales Y/Y TTM | -12.34% | Oper. Margin | -2.88% | ATR (14) | 0.02 | Perf 10Y | -97.01% |
| Dividend Ex-Date | - | Quick Ratio | 0.72 | EPS Q/Q | -249.51% | Profit Margin | -12.24% | RSI (14) | 37.22 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.49 | Sales Q/Q | -20.87% | SMA20 | -12.95% ($0.17) | Beta | 1.38 | Target Price | $0.35 |
| Payout | - | Debt/Eq | 4.5 | Earnings | 2026/11/4 | SMA50 | -33.25% ($0.22) | Rel Volume | 0.28 | Prev Close | $0.14 |
| Employees | 809 | LT Debt/Eq | 4.18 | EPS/Sales Surpr. | - -4.16% | SMA200 | -59.49% ($0.37) | Avg Volume(3M) | 7.20M | Price | $0.15 |
| IPO | 2007/2/8 | Option/Short | Yes/Yes | Trades | 1028 | Volume | 1,988,726 | Change | 5.71% |
🎯 A global radiation oncology-focused medical device company that is revolutionizing the accuracy of cancer treatment through its robotic precision radiosurgery system, the "CyberKnife."
Over the past 1 year, on the lower side
90% below its 1-year high.
Traded less than usual. That is 28% of its average volume.
Next earnings report: November 4
2 days to go.
ARAY has weak earning power
Of every $100 in sales, $2.88 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4. Peers typically go for $145.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.2%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 44.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #108 of 140 in the industry
Based on market cap of $18M.
ARAY#108 Accuray Inc $18M PER - 
ITOC#109 iTonic Holdings Ltd $17M PER - 
MODD#110 Modular Medical Inc $17M PER - 
LFWD#111 Lifeward Ltd $17M PER - 
PAVM#112 PAVmed Inc $15M PER - 
FAQ
What kind of company is ARAY?
ARAY belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of ARAY?
The market cap of ARAY is approximately $18M, ranking 5,245 within its sector.
What is the 52-week high and low for ARAY?
ARAY has recorded a 52-week high of $1.46 and a low of $0.12.
